Empros Pharma has developed a revolutionary drug – EMP16. The main mechanism of action for EMP16 is to delay normal food digestion and absorption processes towards the end of the small intestine. EMP16 is based on a proprietary advanced drug delivery technology, designed to have features that optimizes its effect throughout the gastrointestinal system.
EMP16 is an oral product with a local effect in the gastrointestinal systems. It is a fixed dose combination of two locally active, safe and established active drugs (orlistat and acarbose). The advanced multiple unit, modified release formulation is designed to maximize the effect of the drugs as well as improving tolerability.